IDEXX Laboratories (NASDAQ: IDXX) furnishes Q4 and 2025 results press release

Rhea-AI Filing Summary

IDEXX Laboratories, Inc. filed a Form 8-K after announcing its financial results for the quarter and year ended December 31, 2025. The detailed results are provided in a press release furnished as Exhibit 99.1.

The company specifies that this earnings information is furnished under Item 2.02 of Form 8-K and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The report is signed by Andrew Emerson, Executive Vice President, Chief Financial Officer and Treasurer.

false IDEXX LABORATORIES INC /DE 0000874716 0000874716 2026-02-02 2026-02-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K  

CURRENT REPORT 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 2, 2026

IDEXX LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		000-19271		01-0393723
(State or other jurisdiction		(Commission File Number)		(IRS Employer Identification No.)
of incorporation)

One IDEXX Drive, Westbrook, Maine	04092
(Address of principal executive offices)	(ZIP Code)

207.556.0300

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 par value per share		IDXX		NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On February 2, 2026, IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with general instructions to Form 8-K, the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)           Exhibits

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

Exhibit No. Description of Exhibit

99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,” issued by the Company on February 2, 2026.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IDEXX LABORATORIES, INC.
Date: February 2, 2026	By:	/s/ Andrew Emerson
		Andrew Emerson
		Executive Vice President, Chief Financial Officer and Treasurer

2

FAQ

What did IDEXX Laboratories (IDXX) disclose in its latest Form 8-K?

IDEXX Laboratories disclosed that it announced financial results for the quarter and year ended December 31, 2025, and furnished the full earnings press release as Exhibit 99.1, rather than including detailed figures directly in the core Form 8-K text.

Which period do the IDEXX Laboratories (IDXX) results in this 8-K cover?

The results cover both the quarter and full year ended December 31, 2025. The company states that these financial results were announced and that complete details are contained in the accompanying press release furnished as Exhibit 99.1 to the Form 8-K.

How is the IDEXX Laboratories (IDXX) earnings information treated under SEC rules?

The earnings information is furnished under Item 2.02 of Form 8-K and is expressly stated as not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, which limits associated liability and incorporation into other SEC filings.

Where can investors find the detailed IDEXX (IDXX) quarterly and annual results?

Investors can find full quarterly and annual financial details in the press release furnished as Exhibit 99.1 to the Form 8-K. The main body of the filing only notes the announcement and references Exhibit 99.1 for comprehensive financial information.

Who signed the IDEXX Laboratories (IDXX) Form 8-K for the 2025 results?

The Form 8-K was signed on behalf of IDEXX Laboratories by Andrew Emerson, who serves as Executive Vice President, Chief Financial Officer and Treasurer. His signature confirms the company’s authorization of the furnished earnings disclosure and related exhibit.